Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced it will release its 2024 third quarter financial results on Wednesday, November 6, 2024, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide business updates. Interested parties can access the webcast through Jazz's investor relations website, with registration recommended 15 minutes before the event. The company, headquartered in Dublin, focuses on developing medicines for sleep disorders, epilepsy, and cancer treatments.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 mercoledì 6 novembre 2024, dopo la chiusura del mercato statunitense. L'azienda ospiterà una diretta audio in streaming alle 16:30 ET per discutere i risultati e fornire aggiornamenti aziendali. Le parti interessate possono accedere alla diretta tramite il sito web delle relazioni con gli investitori di Jazz, con registrazione consigliata 15 minuti prima dell'evento. L'azienda, con sede a Dublino, si concentra sullo sviluppo di farmaci per disturbi del sonno, epilessia e trattamenti per il cancro.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el miércoles 6 de noviembre de 2024, después del cierre del mercado estadounidense. La empresa organizará una transmisión de audio en vivo a las 4:30 p.m. ET para discutir los resultados y proporcionar actualizaciones empresariales. Las partes interesadas pueden acceder a la transmisión a través del sitio web de relaciones con inversores de Jazz, con recomendación de registrarse 15 minutos antes del evento. La compañía, con sede en Dublín, se enfoca en desarrollar medicamentos para trastornos del sueño, epilepsia y tratamientos contra el cáncer.
재즈 제약 (Nasdaq: JAZZ)은 2024년 3분기 재무 결과를 2024년 11월 6일 수요일에 미국 시장 마감 후 발표할 예정이라고 발표했습니다. 회사는 결과를 논의하고 사업 업데이트를 제공하기 위해 오후 4시 30분(ET)에 라이브 오디오 웹캐스트를 진행합니다. 관심 있는 분들은 재즈의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 행사 15분 전에 등록하는 것이 좋습니다. 더블린에 본사를 둔 이 회사는 수면 장애, 간질 및 암 치료를 위한 약물 개발에 집중하고 있습니다.
Jazz Pharmaceuticals (Nasdaq: JAZZ) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le mercredi 6 novembre 2024, après la clôture du marché américain. L'entreprise organisera un webinaire en direct à 16h30 (ET) pour discuter des résultats et fournir des mises à jour d'entreprise. Les parties intéressées peuvent accéder au webinaire via le site des relations investisseurs de Jazz, avec une inscription recommandée 15 minutes avant l'événement. L'entreprise, dont le siège est à Dublin, se concentre sur le développement de médicaments pour les troubles du sommeil, l'épilepsie et les traitements contre le cancer.
Jazz Pharmaceuticals (Nasdaq: JAZZ) hat angekündigt, dass es seine Finanzergebnisse für das 3. Quartal 2024 am Mittwoch, den 6. November 2024, nach Börsenschluss in den USA veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET ein Live-Audio-Webcast veranstalten, um die Ergebnisse zu besprechen und Unternehmensupdates zu geben. Interessierte können auf den Webcast über die Investor-Relations-Website von Jazz zugreifen, wobei eine Registrierung 15 Minuten vor der Veranstaltung empfohlen wird. Das Unternehmen mit Hauptsitz in Dublin konzentriert sich auf die Entwicklung von Arzneimitteln für Schlafstörungen, Epilepsie und Krebsbehandlungen.
- None.
- None.
Audio webcast/conference call:
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-third-quarter-financial-results-on-november-6-2024-302284892.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report Q3 2024 earnings?
How can I access Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings call?
What time is Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings call?
